Market Place
Sourcing Support
FDA Confirms Para IV Patent for Selpercatinib (Retevmo) Capsules
11 Jul 2024 //
FDA
Lilly`s Retevmo lands new accelerated approval for pediatric cancers
30 May 2024 //
FDA
ESMO: Lilly drug drives major benefits in lung, thyroid cancers
21 Oct 2023 //
FIERCE PHARMA
Lilly`s Retevmo Ph 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer
21 Oct 2023 //
PR NEWSWIRE
FDA Approves FoundationOne®CDx as a Companion Diagnostic for Lilly’s Retevmo
09 Oct 2023 //
BUSINESSWIRE
Lilly’s Retevmo Shows Superior Survival in Phase III Thyroid Cancer Trial
23 Aug 2023 //
PR NEWSWIRE
Lilly`s Retevmo bests Keytruda combo in front-line RET-rearranged lung cancer
05 Aug 2023 //
PRESS RELEASE
Eli Lilly`s Retsevmo (selpercatinib) Receives Approval in Europe
18 Jul 2023 //
EMA
China’s NMPA approves selpercatinib NDA to treat lung and thyroid cancers
10 Oct 2022 //
PHARMACEUTICAL-TECHNOLOGY
The China NMPA Approves Selpercatinib for the Treatment of Lung Cancers
09 Oct 2022 //
PRNEWSWIRE
Lilly- FDA Approves Retevmo For Adult Patients
23 Sep 2022 //
NASDAQ
FDA Approves Lilly`s Retevmo the First RET Inhibitor with a RET Gene Fusion
22 Sep 2022 //
PRNEWSWIRE
Lilly Announces Details of Presentations at ESMO Congress 2022
07 Sep 2022 //
PRNEWSWIRE
Lilly Presents Updated Data on Retevmo in Advanced RET Fusion-Positive NSCLC
01 Apr 2022 //
PRNEWSWIRE
NICE recommends Lilly’s selpercatinib for rare thyroid cancer treatment
04 Oct 2021 //
PHARMACEUTICAL-TECHNOLOGY
SMC OKs three new meds in latest decisions
14 Sep 2021 //
PHARMATIMES
Lilly’s Retevmo shows encouraging antitumour activity in cancer trial
13 Apr 2021 //
CLINCALTRIALSARENA
Lilly guns for `tissue agnostic` nod for Retevmo
12 Apr 2021 //
FIERCEPHARMA
MHRA authorises Lilly’s RET inhibitor Retsevmo
10 Mar 2021 //
PHARMATIMES
Lilly`s cancer drug Retsevmo gets UK approval for multiple indications
10 Mar 2021 //
PHARMAFILE
Roche, Blueprint match Lilly with Gavreto`s thyroid cancer nod
03 Dec 2020 //
FIERCE PHARMA
New England Journal of Medicine Publishes Phase 1/2 Data for Retevmo™
26 Aug 2020 //
PRNEWSWIRE
FDA approves Eli Lilly drug for thyroid, lung cancers driven by a genetic
08 May 2020 //
REUTERS
Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy
08 May 2020 //
PR NEWSWIRE
FDA Approves First Therapy for Patients with Lung and Thyroid Cancers
08 May 2020 //
FDA
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
29 Jan 2020 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.